FogPharma Revenue and Competitors
Estimated Revenue & Valuation
- FogPharma's estimated annual revenue is currently $17.4M per year.
- FogPharma received $66.0M in venture funding in May 2018.
- FogPharma's estimated revenue per employee is $155,000
- FogPharma's total funding is $184M.
- FogPharma has 112 Employees.
- FogPharma grew their employee count by 26% last year.
What Is FogPharma?
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered undruggable. The company's cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP's to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention. We are a vibrant and driven group of scientists and science lovers, with a strong entrepreneurial spirit, and deeply committed to our mission of adding years to life and life to years through the creation of transformative new medicines.keywords:N/A
Number of Employees
Employee Growth %
After years of operating in the shadow of its more public sister company, FogPharma, LifeMine Therapeutics is making its plans known,...
... avoid rushing the two companies he's now running LifeMine and another early-stage biotech, FogPharma to an IPO before they're ready.
Verdine formally introduced his 2016 startup Fogpharma Inc. in conjunction with the close of a $66 million series B. In March,...
FogPharma has raised $107 million in a round led by VenBio Partners. Based in the Boston area, the company is a developer of precision medicines designed to target cancer-causing proteins. Founded in 2016, the company was valued at $173.2 million in January, according to PitchBook data. Select ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|2018-05-17||$66.0M||B||6 Dimensions Capital||Article|